Rockville, Maryland, April 25, 2024–(BUSINESS WIRE)–Glycomimetics, Inc. (NASDAQ: GLYC) will call today, Thursday, May 9, 2024 at 8:30 a.m. ET to report first quarter 2024 financial results. We announced that we will be hosting a conference and webcast.
To access the call by phone, please visit this registration link. Dial-in details will be provided. Participants are encouraged to connect 15 minutes before the scheduled start time.
A live webcast of the conference call will be available on the Investors tab on the GlycoMimetics website. A replay of the webcast will be available for 30 days after the call.
About GlycoMimetics, Inc.
GlycoMimetics is a late-stage clinical biotechnology company discovering and developing glycobiology-based therapies for cancer and inflammatory diseases, including AML. The company's scientific approach is based on understanding the role carbohydrates play in cellular recognition. The company's specialized chemistry platform is deployed to discover small molecule drugs, known as glycomimetics, that alter carbohydrate-mediated recognition in a variety of disease states, including cancer and inflammation. GlycoMimetics leverages its differentiated expertise in this scientific approach to advance its wholly-owned pipeline of drug candidates. The company's goal is to develop innovative treatments for diseases with high unmet medical need. GlycoMimetics is headquartered in Rockville, Maryland, in the BioHealth Capital Region. For more information, please visit www.glycomimetics.com.
View source version on businesswire.com. https://www.businesswire.com/news/home/20240425404134/ja/
contact address
Investor contact information:
Argot Partners
leo bartrella
212-600-1902
Glycomimetics@argotpartners.com
